Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204120014> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W3204120014 abstract "Abstract BACKGROUND: To compare the efficacy and safety of gemcitabine and epirubicin curing for patients with non muscle invasive bladder cancer (NMIBC). METHODS: from October 2014 to October 2017, 86 patients with non muscle invasive bladder cancer diagnosed by transurethral resection of bladder tumor(TURBT), in urology department of Wenling Hospital Affiliated to Wenzhou Medical University were analyzed retrospectively. Among them, 42 were treated with gemcitabine and the other 44 with epirubicin. The two groups were treated with epirubicin or gemcitabine within 24 hours after operation, and bladder perfusion once a week was performed continuously after the first week of operation, a total of 8 times,and after that once a month till one year after operation. The clinical efficacy and adverse reactions of the two groups were compared. Kaplan-Meier was used to compare the recurrence free survival time of tumor after operation and Cox proportional risk model was used to analyze various factors affecting the prognosis. RESULTS: 1. There was no significant difference between the two groups (P > 0.05). 2. The adverse reactions of the two groups were mainly bladder irritation, gross hematuria, fever, nausea and vomiting. The incidence of bladder irritation and gross hematuria in epirubicin group was significantly higher than those in gemcitabine group (P < 0.05),which meant it had statistical significance. There was no significant difference on the other side-effects between the two groups (P > 0.05). 3. The results of Kaplan-Meier survival analysis showed that the median tumor recurrence free survival time of gemcitabine group was 29.7 months, the one-year tumor recurrence free survival rate was 81%, and the two-year tumor recurrence free survival rate was 57%; while the median tumor recurrence free survival time of epirubicin group was 28.8 months, the one-year tumor recurrence free survival rate was 72%, and the two-year tumor recurrence free survival rate was 50%.Multivariate Cox analysis also showed that age ,as well as tumor grade was independent risk factors for prognosis. CONCLUSION:Gemcitabine assisted with intravesical instillation chemotherapy is more effective with fewer side-effects, which is worthy of further study. Age and tumor grade are independent risk factors for prognosis." @default.
- W3204120014 created "2021-10-11" @default.
- W3204120014 creator A5042241049 @default.
- W3204120014 creator A5047544514 @default.
- W3204120014 creator A5065761001 @default.
- W3204120014 date "2020-04-07" @default.
- W3204120014 modified "2023-10-17" @default.
- W3204120014 title "A comparative study of gemcitabine and epirubicin in adjuvant chemotherapy of non muscle invasive bladder cancer" @default.
- W3204120014 doi "https://doi.org/10.21203/rs.3.rs-20323/v1" @default.
- W3204120014 hasPublicationYear "2020" @default.
- W3204120014 type Work @default.
- W3204120014 sameAs 3204120014 @default.
- W3204120014 citedByCount "0" @default.
- W3204120014 crossrefType "posted-content" @default.
- W3204120014 hasAuthorship W3204120014A5042241049 @default.
- W3204120014 hasAuthorship W3204120014A5047544514 @default.
- W3204120014 hasAuthorship W3204120014A5065761001 @default.
- W3204120014 hasBestOaLocation W32041200141 @default.
- W3204120014 hasConcept C121608353 @default.
- W3204120014 hasConcept C126322002 @default.
- W3204120014 hasConcept C126894567 @default.
- W3204120014 hasConcept C143998085 @default.
- W3204120014 hasConcept C2776694085 @default.
- W3204120014 hasConcept C2780258809 @default.
- W3204120014 hasConcept C2780352672 @default.
- W3204120014 hasConcept C2780580376 @default.
- W3204120014 hasConcept C2780835546 @default.
- W3204120014 hasConcept C530470458 @default.
- W3204120014 hasConcept C71924100 @default.
- W3204120014 hasConceptScore W3204120014C121608353 @default.
- W3204120014 hasConceptScore W3204120014C126322002 @default.
- W3204120014 hasConceptScore W3204120014C126894567 @default.
- W3204120014 hasConceptScore W3204120014C143998085 @default.
- W3204120014 hasConceptScore W3204120014C2776694085 @default.
- W3204120014 hasConceptScore W3204120014C2780258809 @default.
- W3204120014 hasConceptScore W3204120014C2780352672 @default.
- W3204120014 hasConceptScore W3204120014C2780580376 @default.
- W3204120014 hasConceptScore W3204120014C2780835546 @default.
- W3204120014 hasConceptScore W3204120014C530470458 @default.
- W3204120014 hasConceptScore W3204120014C71924100 @default.
- W3204120014 hasLocation W32041200141 @default.
- W3204120014 hasOpenAccess W3204120014 @default.
- W3204120014 hasPrimaryLocation W32041200141 @default.
- W3204120014 hasRelatedWork W2027059918 @default.
- W3204120014 hasRelatedWork W2080820783 @default.
- W3204120014 hasRelatedWork W2113566724 @default.
- W3204120014 hasRelatedWork W2122063636 @default.
- W3204120014 hasRelatedWork W2381102807 @default.
- W3204120014 hasRelatedWork W3204120014 @default.
- W3204120014 hasRelatedWork W4234631976 @default.
- W3204120014 hasRelatedWork W4303057512 @default.
- W3204120014 hasRelatedWork W4313197990 @default.
- W3204120014 hasRelatedWork W2118673085 @default.
- W3204120014 isParatext "false" @default.
- W3204120014 isRetracted "false" @default.
- W3204120014 magId "3204120014" @default.
- W3204120014 workType "article" @default.